Interactive R&D portfolio

MMV’s portfolio focuses on delivering efficacious medicines that are affordable, accessible and appropriate for use in malaria endemic areas. Specifically, the goal is to develop products that will provide: efficacy against drug-resistant strains of Plasmodium falciparum, potential for intermittent treatments (infants and pregnancy), safety in small children (less than 6 months old), safety in pregnancy, efficacy against Plasmodium vivax (including radical cure), efficacy against severe malaria, and transmission-blocking treatment.

The MMV project portfolio is updated quarterly. Click on a project below for more information.

For more information about the global malaria portfolio, read the article: The Global Portfolio of New Antimalarial Medicines Under Development.


Legend

MP - miniportfolio: MMV pioneered the miniportfolio model. The model assures flexibility in allocation of resources – established between MMV and a Pharmaceutical or Biotechnology partner – from one project to another. In this way, resources are utilized as efficiently as possible.

* First approval by WHO Prequalification, or by regulatory bodies who are ICH members or observers

- Included in MMV portfolio post registration.

1 Brand name: Coartem® Dispersible, Generic by Ajanta
2 Brand name: Artesun®
3 Brand name: Eurartesim®
4 Brand name: Pyramax® 
5 Brand names: CoarsucamTM, ASAQ/Winthrop®, FDC generics by Ajanta, Ipca, Guilin, Co-blistered generics by Strides, Cipla
6 Also Acino/Mepha product (co-blistered)